Immuneel Therapeutics
PrivateLast Round
Series B
Jun 8, 2026
Est. Valuation
$71M
Total Funding Raised
$52.65M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Immuneel Therapeutics operates in Healthcare & Life Sciences and is based in Bangalore. Its latest recorded funding round was a Series B round in June 2026.
Immuneel Therapeutics is a biotechnology company that develops affordable cell and gene therapies, including CAR-T therapies, for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immuneel Therapeutics Comparables
Compare Immuneel Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ImmunoACT | 89% | |
| Cellogen Therapeutics | 85% | |
| AbelZeta Pharma | 78% |
For institutional investors. Book with your work email.
Immuneel Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 8, 2026 | ||||
| Grant | Jun 10, 2025 | ||||
| Series A Extension | Jul 10, 2024 | ||||
| Series A | Jun 21, 2022 | ||||
| Seed | Jan 8, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immuneel Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rainmatter Capital Fund | Series B |
| F-Prime Capital | Series A, Seed |
| Eight Roads Ventures | Series B, Series A, Seed |
| Singularity AMC | Series B |
| F-Prime Capital | Series B, Series A |
| True North | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 311% MoM, reaching 14.2K.
- Jan 8, 2026
Partnered with healthcare lending marketplace CarePal Money.
For institutional investors. Book with your work email.
Immuneel Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immuneel Therapeutics's valuation, stock price, and market status.
Is Immuneel Therapeutics a public or private company?
Immuneel Therapeutics is a private company.
What is the current stock price of Immuneel Therapeutics?
Immuneel Therapeutics is a private company, so its shares have no public market price. Caplight tracks Immuneel Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immuneel Therapeutics worth (valuation)?
Immuneel Therapeutics's valuation is estimated at $71.0M based on funding round data.
Can I buy Immuneel Therapeutics stock?
Immuneel Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immuneel Therapeutics's last funding round?
Immuneel Therapeutics's most recent funding round was Series B on June 8, 2026.
Who are the main investors in Immuneel Therapeutics?
Key investors in Immuneel Therapeutics include Rainmatter Capital Fund, F-Prime Capital, Eight Roads Ventures, Singularity AMC, F-Prime Capital.
Will Immuneel Therapeutics IPO soon?
No public IPO plans have been announced for Immuneel Therapeutics.
How can I track Immuneel Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Immuneel Therapeutics's shares on secondary markets.